Global Neurodegenerative Diseases Therapeutics Market Growth (Status and Outlook) 2024-2030
The report requires updating with new data and is sent in 48 hours after order is placed.
According to our LPI (LP Information) latest study, the global Neurodegenerative Diseases Therapeutics market size was valued at US$ million in 2023. With growing demand in downstream market, the Neurodegenerative Diseases Therapeutics is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period.
The research report highlights the growth potential of the global Neurodegenerative Diseases Therapeutics market. Neurodegenerative Diseases Therapeutics are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Neurodegenerative Diseases Therapeutics. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Neurodegenerative Diseases Therapeutics market.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Key Features:
The report on Neurodegenerative Diseases Therapeutics market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Neurodegenerative Diseases Therapeutics market. It may include historical data, market segmentation by Type (e.g., Multiple Sclerosis Therapeutics, Alzheimer's Disease Therapeutics), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Neurodegenerative Diseases Therapeutics market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Neurodegenerative Diseases Therapeutics market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Neurodegenerative Diseases Therapeutics industry. This include advancements in Neurodegenerative Diseases Therapeutics technology, Neurodegenerative Diseases Therapeutics new entrants, Neurodegenerative Diseases Therapeutics new investment, and other innovations that are shaping the future of Neurodegenerative Diseases Therapeutics.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Neurodegenerative Diseases Therapeutics market. It includes factors influencing customer ' purchasing decisions, preferences for Neurodegenerative Diseases Therapeutics product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Neurodegenerative Diseases Therapeutics market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Neurodegenerative Diseases Therapeutics market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Neurodegenerative Diseases Therapeutics market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Neurodegenerative Diseases Therapeutics industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Neurodegenerative Diseases Therapeutics market.
Market Segmentation:
Neurodegenerative Diseases Therapeutics market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Segmentation by type
According to our LPI (LP Information) latest study, the global Neurodegenerative Diseases Therapeutics market size was valued at US$ million in 2023. With growing demand in downstream market, the Neurodegenerative Diseases Therapeutics is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period.
The research report highlights the growth potential of the global Neurodegenerative Diseases Therapeutics market. Neurodegenerative Diseases Therapeutics are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Neurodegenerative Diseases Therapeutics. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Neurodegenerative Diseases Therapeutics market.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Key Features:
The report on Neurodegenerative Diseases Therapeutics market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Neurodegenerative Diseases Therapeutics market. It may include historical data, market segmentation by Type (e.g., Multiple Sclerosis Therapeutics, Alzheimer's Disease Therapeutics), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Neurodegenerative Diseases Therapeutics market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Neurodegenerative Diseases Therapeutics market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Neurodegenerative Diseases Therapeutics industry. This include advancements in Neurodegenerative Diseases Therapeutics technology, Neurodegenerative Diseases Therapeutics new entrants, Neurodegenerative Diseases Therapeutics new investment, and other innovations that are shaping the future of Neurodegenerative Diseases Therapeutics.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Neurodegenerative Diseases Therapeutics market. It includes factors influencing customer ' purchasing decisions, preferences for Neurodegenerative Diseases Therapeutics product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Neurodegenerative Diseases Therapeutics market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Neurodegenerative Diseases Therapeutics market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Neurodegenerative Diseases Therapeutics market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Neurodegenerative Diseases Therapeutics industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Neurodegenerative Diseases Therapeutics market.
Market Segmentation:
Neurodegenerative Diseases Therapeutics market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Segmentation by type
- Multiple Sclerosis Therapeutics
- Alzheimer's Disease Therapeutics
- Parkinson's Disease Therapeutics
- Parkinson's Disease Therapeutics
- Others
- Child
- Aldult
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- AB Science SA
- AbbVie Inc.
- Acadia Pharmaceuticals Inc.
- Biogen Inc.
- F. Hoffmann La Roche Ltd.
- H Lundbeck AS
- Mitsubishi Chemical Holdings Corp.
- Novartis AG
- Sanofi
- Teva Pharmaceutical Industries Ltd
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Neurodegenerative Diseases Therapeutics Market Size 2019-2030
2.1.2 Neurodegenerative Diseases Therapeutics Market Size CAGR by Region 2019 VS 2023 VS 2030
2.2 Neurodegenerative Diseases Therapeutics Segment by Type
2.2.1 Multiple Sclerosis Therapeutics
2.2.2 Alzheimer's Disease Therapeutics
2.2.3 Parkinson's Disease Therapeutics
2.2.4 Parkinson's Disease Therapeutics
2.2.5 Others
2.3 Neurodegenerative Diseases Therapeutics Market Size by Type
2.3.1 Neurodegenerative Diseases Therapeutics Market Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Neurodegenerative Diseases Therapeutics Market Size Market Share by Type (2019-2024)
2.4 Neurodegenerative Diseases Therapeutics Segment by Application
2.4.1 Child
2.4.2 Aldult
2.5 Neurodegenerative Diseases Therapeutics Market Size by Application
2.5.1 Neurodegenerative Diseases Therapeutics Market Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Neurodegenerative Diseases Therapeutics Market Size Market Share by Application (2019-2024)
3 NEURODEGENERATIVE DISEASES THERAPEUTICS MARKET SIZE BY PLAYER
3.1 Neurodegenerative Diseases Therapeutics Market Size Market Share by Players
3.1.1 Global Neurodegenerative Diseases Therapeutics Revenue by Players (2019-2024)
3.1.2 Global Neurodegenerative Diseases Therapeutics Revenue Market Share by Players (2019-2024)
3.2 Global Neurodegenerative Diseases Therapeutics Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 NEURODEGENERATIVE DISEASES THERAPEUTICS BY REGIONS
4.1 Neurodegenerative Diseases Therapeutics Market Size by Regions (2019-2024)
4.2 Americas Neurodegenerative Diseases Therapeutics Market Size Growth (2019-2024)
4.3 APAC Neurodegenerative Diseases Therapeutics Market Size Growth (2019-2024)
4.4 Europe Neurodegenerative Diseases Therapeutics Market Size Growth (2019-2024)
4.5 Middle East & Africa Neurodegenerative Diseases Therapeutics Market Size Growth (2019-2024)
5 AMERICAS
5.1 Americas Neurodegenerative Diseases Therapeutics Market Size by Country (2019-2024)
5.2 Americas Neurodegenerative Diseases Therapeutics Market Size by Type (2019-2024)
5.3 Americas Neurodegenerative Diseases Therapeutics Market Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Neurodegenerative Diseases Therapeutics Market Size by Region (2019-2024)
6.2 APAC Neurodegenerative Diseases Therapeutics Market Size by Type (2019-2024)
6.3 APAC Neurodegenerative Diseases Therapeutics Market Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Neurodegenerative Diseases Therapeutics by Country (2019-2024)
7.2 Europe Neurodegenerative Diseases Therapeutics Market Size by Type (2019-2024)
7.3 Europe Neurodegenerative Diseases Therapeutics Market Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Neurodegenerative Diseases Therapeutics by Region (2019-2024)
8.2 Middle East & Africa Neurodegenerative Diseases Therapeutics Market Size by Type (2019-2024)
8.3 Middle East & Africa Neurodegenerative Diseases Therapeutics Market Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL NEURODEGENERATIVE DISEASES THERAPEUTICS MARKET FORECAST
10.1 Global Neurodegenerative Diseases Therapeutics Forecast by Regions (2025-2030)
10.1.1 Global Neurodegenerative Diseases Therapeutics Forecast by Regions (2025-2030)
10.1.2 Americas Neurodegenerative Diseases Therapeutics Forecast
10.1.3 APAC Neurodegenerative Diseases Therapeutics Forecast
10.1.4 Europe Neurodegenerative Diseases Therapeutics Forecast
10.1.5 Middle East & Africa Neurodegenerative Diseases Therapeutics Forecast
10.2 Americas Neurodegenerative Diseases Therapeutics Forecast by Country (2025-2030)
10.2.1 United States Neurodegenerative Diseases Therapeutics Market Forecast
10.2.2 Canada Neurodegenerative Diseases Therapeutics Market Forecast
10.2.3 Mexico Neurodegenerative Diseases Therapeutics Market Forecast
10.2.4 Brazil Neurodegenerative Diseases Therapeutics Market Forecast
10.3 APAC Neurodegenerative Diseases Therapeutics Forecast by Region (2025-2030)
10.3.1 China Neurodegenerative Diseases Therapeutics Market Forecast
10.3.2 Japan Neurodegenerative Diseases Therapeutics Market Forecast
10.3.3 Korea Neurodegenerative Diseases Therapeutics Market Forecast
10.3.4 Southeast Asia Neurodegenerative Diseases Therapeutics Market Forecast
10.3.5 India Neurodegenerative Diseases Therapeutics Market Forecast
10.3.6 Australia Neurodegenerative Diseases Therapeutics Market Forecast
10.4 Europe Neurodegenerative Diseases Therapeutics Forecast by Country (2025-2030)
10.4.1 Germany Neurodegenerative Diseases Therapeutics Market Forecast
10.4.2 France Neurodegenerative Diseases Therapeutics Market Forecast
10.4.3 UK Neurodegenerative Diseases Therapeutics Market Forecast
10.4.4 Italy Neurodegenerative Diseases Therapeutics Market Forecast
10.4.5 Russia Neurodegenerative Diseases Therapeutics Market Forecast
10.5 Middle East & Africa Neurodegenerative Diseases Therapeutics Forecast by Region (2025-2030)
10.5.1 Egypt Neurodegenerative Diseases Therapeutics Market Forecast
10.5.2 South Africa Neurodegenerative Diseases Therapeutics Market Forecast
10.5.3 Israel Neurodegenerative Diseases Therapeutics Market Forecast
10.5.4 Turkey Neurodegenerative Diseases Therapeutics Market Forecast
10.5.5 GCC Countries Neurodegenerative Diseases Therapeutics Market Forecast
10.6 Global Neurodegenerative Diseases Therapeutics Forecast by Type (2025-2030)
10.7 Global Neurodegenerative Diseases Therapeutics Forecast by Application (2025-2030)
11 KEY PLAYERS ANALYSIS
11.1 AB Science SA
11.1.1 AB Science SA Company Information
11.1.2 AB Science SA Neurodegenerative Diseases Therapeutics Product Offered
11.1.3 AB Science SA Neurodegenerative Diseases Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.1.4 AB Science SA Main Business Overview
11.1.5 AB Science SA Latest Developments
11.2 AbbVie Inc.
11.2.1 AbbVie Inc. Company Information
11.2.2 AbbVie Inc. Neurodegenerative Diseases Therapeutics Product Offered
11.2.3 AbbVie Inc. Neurodegenerative Diseases Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.2.4 AbbVie Inc. Main Business Overview
11.2.5 AbbVie Inc. Latest Developments
11.3 Acadia Pharmaceuticals Inc.
11.3.1 Acadia Pharmaceuticals Inc. Company Information
11.3.2 Acadia Pharmaceuticals Inc. Neurodegenerative Diseases Therapeutics Product Offered
11.3.3 Acadia Pharmaceuticals Inc. Neurodegenerative Diseases Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.3.4 Acadia Pharmaceuticals Inc. Main Business Overview
11.3.5 Acadia Pharmaceuticals Inc. Latest Developments
11.4 Biogen Inc.
11.4.1 Biogen Inc. Company Information
11.4.2 Biogen Inc. Neurodegenerative Diseases Therapeutics Product Offered
11.4.3 Biogen Inc. Neurodegenerative Diseases Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.4.4 Biogen Inc. Main Business Overview
11.4.5 Biogen Inc. Latest Developments
11.5 F. Hoffmann La Roche Ltd.
11.5.1 F. Hoffmann La Roche Ltd. Company Information
11.5.2 F. Hoffmann La Roche Ltd. Neurodegenerative Diseases Therapeutics Product Offered
11.5.3 F. Hoffmann La Roche Ltd. Neurodegenerative Diseases Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.5.4 F. Hoffmann La Roche Ltd. Main Business Overview
11.5.5 F. Hoffmann La Roche Ltd. Latest Developments
11.6 H Lundbeck AS
11.6.1 H Lundbeck AS Company Information
11.6.2 H Lundbeck AS Neurodegenerative Diseases Therapeutics Product Offered
11.6.3 H Lundbeck AS Neurodegenerative Diseases Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.6.4 H Lundbeck AS Main Business Overview
11.6.5 H Lundbeck AS Latest Developments
11.7 Mitsubishi Chemical Holdings Corp.
11.7.1 Mitsubishi Chemical Holdings Corp. Company Information
11.7.2 Mitsubishi Chemical Holdings Corp. Neurodegenerative Diseases Therapeutics Product Offered
11.7.3 Mitsubishi Chemical Holdings Corp. Neurodegenerative Diseases Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.7.4 Mitsubishi Chemical Holdings Corp. Main Business Overview
11.7.5 Mitsubishi Chemical Holdings Corp. Latest Developments
11.8 Novartis AG
11.8.1 Novartis AG Company Information
11.8.2 Novartis AG Neurodegenerative Diseases Therapeutics Product Offered
11.8.3 Novartis AG Neurodegenerative Diseases Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.8.4 Novartis AG Main Business Overview
11.8.5 Novartis AG Latest Developments
11.9 Sanofi
11.9.1 Sanofi Company Information
11.9.2 Sanofi Neurodegenerative Diseases Therapeutics Product Offered
11.9.3 Sanofi Neurodegenerative Diseases Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.9.4 Sanofi Main Business Overview
11.9.5 Sanofi Latest Developments
11.10 Teva Pharmaceutical Industries Ltd
11.10.1 Teva Pharmaceutical Industries Ltd Company Information
11.10.2 Teva Pharmaceutical Industries Ltd Neurodegenerative Diseases Therapeutics Product Offered
11.10.3 Teva Pharmaceutical Industries Ltd Neurodegenerative Diseases Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.10.4 Teva Pharmaceutical Industries Ltd Main Business Overview
11.10.5 Teva Pharmaceutical Industries Ltd Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Neurodegenerative Diseases Therapeutics Market Size 2019-2030
2.1.2 Neurodegenerative Diseases Therapeutics Market Size CAGR by Region 2019 VS 2023 VS 2030
2.2 Neurodegenerative Diseases Therapeutics Segment by Type
2.2.1 Multiple Sclerosis Therapeutics
2.2.2 Alzheimer's Disease Therapeutics
2.2.3 Parkinson's Disease Therapeutics
2.2.4 Parkinson's Disease Therapeutics
2.2.5 Others
2.3 Neurodegenerative Diseases Therapeutics Market Size by Type
2.3.1 Neurodegenerative Diseases Therapeutics Market Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Neurodegenerative Diseases Therapeutics Market Size Market Share by Type (2019-2024)
2.4 Neurodegenerative Diseases Therapeutics Segment by Application
2.4.1 Child
2.4.2 Aldult
2.5 Neurodegenerative Diseases Therapeutics Market Size by Application
2.5.1 Neurodegenerative Diseases Therapeutics Market Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Neurodegenerative Diseases Therapeutics Market Size Market Share by Application (2019-2024)
3 NEURODEGENERATIVE DISEASES THERAPEUTICS MARKET SIZE BY PLAYER
3.1 Neurodegenerative Diseases Therapeutics Market Size Market Share by Players
3.1.1 Global Neurodegenerative Diseases Therapeutics Revenue by Players (2019-2024)
3.1.2 Global Neurodegenerative Diseases Therapeutics Revenue Market Share by Players (2019-2024)
3.2 Global Neurodegenerative Diseases Therapeutics Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 NEURODEGENERATIVE DISEASES THERAPEUTICS BY REGIONS
4.1 Neurodegenerative Diseases Therapeutics Market Size by Regions (2019-2024)
4.2 Americas Neurodegenerative Diseases Therapeutics Market Size Growth (2019-2024)
4.3 APAC Neurodegenerative Diseases Therapeutics Market Size Growth (2019-2024)
4.4 Europe Neurodegenerative Diseases Therapeutics Market Size Growth (2019-2024)
4.5 Middle East & Africa Neurodegenerative Diseases Therapeutics Market Size Growth (2019-2024)
5 AMERICAS
5.1 Americas Neurodegenerative Diseases Therapeutics Market Size by Country (2019-2024)
5.2 Americas Neurodegenerative Diseases Therapeutics Market Size by Type (2019-2024)
5.3 Americas Neurodegenerative Diseases Therapeutics Market Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Neurodegenerative Diseases Therapeutics Market Size by Region (2019-2024)
6.2 APAC Neurodegenerative Diseases Therapeutics Market Size by Type (2019-2024)
6.3 APAC Neurodegenerative Diseases Therapeutics Market Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Neurodegenerative Diseases Therapeutics by Country (2019-2024)
7.2 Europe Neurodegenerative Diseases Therapeutics Market Size by Type (2019-2024)
7.3 Europe Neurodegenerative Diseases Therapeutics Market Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Neurodegenerative Diseases Therapeutics by Region (2019-2024)
8.2 Middle East & Africa Neurodegenerative Diseases Therapeutics Market Size by Type (2019-2024)
8.3 Middle East & Africa Neurodegenerative Diseases Therapeutics Market Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL NEURODEGENERATIVE DISEASES THERAPEUTICS MARKET FORECAST
10.1 Global Neurodegenerative Diseases Therapeutics Forecast by Regions (2025-2030)
10.1.1 Global Neurodegenerative Diseases Therapeutics Forecast by Regions (2025-2030)
10.1.2 Americas Neurodegenerative Diseases Therapeutics Forecast
10.1.3 APAC Neurodegenerative Diseases Therapeutics Forecast
10.1.4 Europe Neurodegenerative Diseases Therapeutics Forecast
10.1.5 Middle East & Africa Neurodegenerative Diseases Therapeutics Forecast
10.2 Americas Neurodegenerative Diseases Therapeutics Forecast by Country (2025-2030)
10.2.1 United States Neurodegenerative Diseases Therapeutics Market Forecast
10.2.2 Canada Neurodegenerative Diseases Therapeutics Market Forecast
10.2.3 Mexico Neurodegenerative Diseases Therapeutics Market Forecast
10.2.4 Brazil Neurodegenerative Diseases Therapeutics Market Forecast
10.3 APAC Neurodegenerative Diseases Therapeutics Forecast by Region (2025-2030)
10.3.1 China Neurodegenerative Diseases Therapeutics Market Forecast
10.3.2 Japan Neurodegenerative Diseases Therapeutics Market Forecast
10.3.3 Korea Neurodegenerative Diseases Therapeutics Market Forecast
10.3.4 Southeast Asia Neurodegenerative Diseases Therapeutics Market Forecast
10.3.5 India Neurodegenerative Diseases Therapeutics Market Forecast
10.3.6 Australia Neurodegenerative Diseases Therapeutics Market Forecast
10.4 Europe Neurodegenerative Diseases Therapeutics Forecast by Country (2025-2030)
10.4.1 Germany Neurodegenerative Diseases Therapeutics Market Forecast
10.4.2 France Neurodegenerative Diseases Therapeutics Market Forecast
10.4.3 UK Neurodegenerative Diseases Therapeutics Market Forecast
10.4.4 Italy Neurodegenerative Diseases Therapeutics Market Forecast
10.4.5 Russia Neurodegenerative Diseases Therapeutics Market Forecast
10.5 Middle East & Africa Neurodegenerative Diseases Therapeutics Forecast by Region (2025-2030)
10.5.1 Egypt Neurodegenerative Diseases Therapeutics Market Forecast
10.5.2 South Africa Neurodegenerative Diseases Therapeutics Market Forecast
10.5.3 Israel Neurodegenerative Diseases Therapeutics Market Forecast
10.5.4 Turkey Neurodegenerative Diseases Therapeutics Market Forecast
10.5.5 GCC Countries Neurodegenerative Diseases Therapeutics Market Forecast
10.6 Global Neurodegenerative Diseases Therapeutics Forecast by Type (2025-2030)
10.7 Global Neurodegenerative Diseases Therapeutics Forecast by Application (2025-2030)
11 KEY PLAYERS ANALYSIS
11.1 AB Science SA
11.1.1 AB Science SA Company Information
11.1.2 AB Science SA Neurodegenerative Diseases Therapeutics Product Offered
11.1.3 AB Science SA Neurodegenerative Diseases Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.1.4 AB Science SA Main Business Overview
11.1.5 AB Science SA Latest Developments
11.2 AbbVie Inc.
11.2.1 AbbVie Inc. Company Information
11.2.2 AbbVie Inc. Neurodegenerative Diseases Therapeutics Product Offered
11.2.3 AbbVie Inc. Neurodegenerative Diseases Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.2.4 AbbVie Inc. Main Business Overview
11.2.5 AbbVie Inc. Latest Developments
11.3 Acadia Pharmaceuticals Inc.
11.3.1 Acadia Pharmaceuticals Inc. Company Information
11.3.2 Acadia Pharmaceuticals Inc. Neurodegenerative Diseases Therapeutics Product Offered
11.3.3 Acadia Pharmaceuticals Inc. Neurodegenerative Diseases Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.3.4 Acadia Pharmaceuticals Inc. Main Business Overview
11.3.5 Acadia Pharmaceuticals Inc. Latest Developments
11.4 Biogen Inc.
11.4.1 Biogen Inc. Company Information
11.4.2 Biogen Inc. Neurodegenerative Diseases Therapeutics Product Offered
11.4.3 Biogen Inc. Neurodegenerative Diseases Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.4.4 Biogen Inc. Main Business Overview
11.4.5 Biogen Inc. Latest Developments
11.5 F. Hoffmann La Roche Ltd.
11.5.1 F. Hoffmann La Roche Ltd. Company Information
11.5.2 F. Hoffmann La Roche Ltd. Neurodegenerative Diseases Therapeutics Product Offered
11.5.3 F. Hoffmann La Roche Ltd. Neurodegenerative Diseases Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.5.4 F. Hoffmann La Roche Ltd. Main Business Overview
11.5.5 F. Hoffmann La Roche Ltd. Latest Developments
11.6 H Lundbeck AS
11.6.1 H Lundbeck AS Company Information
11.6.2 H Lundbeck AS Neurodegenerative Diseases Therapeutics Product Offered
11.6.3 H Lundbeck AS Neurodegenerative Diseases Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.6.4 H Lundbeck AS Main Business Overview
11.6.5 H Lundbeck AS Latest Developments
11.7 Mitsubishi Chemical Holdings Corp.
11.7.1 Mitsubishi Chemical Holdings Corp. Company Information
11.7.2 Mitsubishi Chemical Holdings Corp. Neurodegenerative Diseases Therapeutics Product Offered
11.7.3 Mitsubishi Chemical Holdings Corp. Neurodegenerative Diseases Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.7.4 Mitsubishi Chemical Holdings Corp. Main Business Overview
11.7.5 Mitsubishi Chemical Holdings Corp. Latest Developments
11.8 Novartis AG
11.8.1 Novartis AG Company Information
11.8.2 Novartis AG Neurodegenerative Diseases Therapeutics Product Offered
11.8.3 Novartis AG Neurodegenerative Diseases Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.8.4 Novartis AG Main Business Overview
11.8.5 Novartis AG Latest Developments
11.9 Sanofi
11.9.1 Sanofi Company Information
11.9.2 Sanofi Neurodegenerative Diseases Therapeutics Product Offered
11.9.3 Sanofi Neurodegenerative Diseases Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.9.4 Sanofi Main Business Overview
11.9.5 Sanofi Latest Developments
11.10 Teva Pharmaceutical Industries Ltd
11.10.1 Teva Pharmaceutical Industries Ltd Company Information
11.10.2 Teva Pharmaceutical Industries Ltd Neurodegenerative Diseases Therapeutics Product Offered
11.10.3 Teva Pharmaceutical Industries Ltd Neurodegenerative Diseases Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.10.4 Teva Pharmaceutical Industries Ltd Main Business Overview
11.10.5 Teva Pharmaceutical Industries Ltd Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Neurodegenerative Diseases Therapeutics Market Size CAGR by Region (2019 VS 2023 VS 2030) & ($ Millions)
Table 2. Major Players of Multiple Sclerosis Therapeutics
Table 3. Major Players of Alzheimer's Disease Therapeutics
Table 4. Major Players of Parkinson's Disease Therapeutics
Table 5. Major Players of Parkinson's Disease Therapeutics
Table 6. Major Players of Others
Table 7. Neurodegenerative Diseases Therapeutics Market Size CAGR by Type (2019 VS 2023 VS 2030) & ($ Millions)
Table 8. Global Neurodegenerative Diseases Therapeutics Market Size by Type (2019-2024) & ($ Millions)
Table 9. Global Neurodegenerative Diseases Therapeutics Market Size Market Share by Type (2019-2024)
Table 10. Neurodegenerative Diseases Therapeutics Market Size CAGR by Application (2019 VS 2023 VS 2030) & ($ Millions)
Table 11. Global Neurodegenerative Diseases Therapeutics Market Size by Application (2019-2024) & ($ Millions)
Table 12. Global Neurodegenerative Diseases Therapeutics Market Size Market Share by Application (2019-2024)
Table 13. Global Neurodegenerative Diseases Therapeutics Revenue by Players (2019-2024) & ($ Millions)
Table 14. Global Neurodegenerative Diseases Therapeutics Revenue Market Share by Player (2019-2024)
Table 15. Neurodegenerative Diseases Therapeutics Key Players Head office and Products Offered
Table 16. Neurodegenerative Diseases Therapeutics Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
Table 17. New Products and Potential Entrants
Table 18. Mergers & Acquisitions, Expansion
Table 19. Global Neurodegenerative Diseases Therapeutics Market Size by Regions 2019-2024 & ($ Millions)
Table 20. Global Neurodegenerative Diseases Therapeutics Market Size Market Share by Regions (2019-2024)
Table 21. Global Neurodegenerative Diseases Therapeutics Revenue by Country/Region (2019-2024) & ($ millions)
Table 22. Global Neurodegenerative Diseases Therapeutics Revenue Market Share by Country/Region (2019-2024)
Table 23. Americas Neurodegenerative Diseases Therapeutics Market Size by Country (2019-2024) & ($ Millions)
Table 24. Americas Neurodegenerative Diseases Therapeutics Market Size Market Share by Country (2019-2024)
Table 25. Americas Neurodegenerative Diseases Therapeutics Market Size by Type (2019-2024) & ($ Millions)
Table 26. Americas Neurodegenerative Diseases Therapeutics Market Size Market Share by Type (2019-2024)
Table 27. Americas Neurodegenerative Diseases Therapeutics Market Size by Application (2019-2024) & ($ Millions)
Table 28. Americas Neurodegenerative Diseases Therapeutics Market Size Market Share by Application (2019-2024)
Table 29. APAC Neurodegenerative Diseases Therapeutics Market Size by Region (2019-2024) & ($ Millions)
Table 30. APAC Neurodegenerative Diseases Therapeutics Market Size Market Share by Region (2019-2024)
Table 31. APAC Neurodegenerative Diseases Therapeutics Market Size by Type (2019-2024) & ($ Millions)
Table 32. APAC Neurodegenerative Diseases Therapeutics Market Size Market Share by Type (2019-2024)
Table 33. APAC Neurodegenerative Diseases Therapeutics Market Size by Application (2019-2024) & ($ Millions)
Table 34. APAC Neurodegenerative Diseases Therapeutics Market Size Market Share by Application (2019-2024)
Table 35. Europe Neurodegenerative Diseases Therapeutics Market Size by Country (2019-2024) & ($ Millions)
Table 36. Europe Neurodegenerative Diseases Therapeutics Market Size Market Share by Country (2019-2024)
Table 37. Europe Neurodegenerative Diseases Therapeutics Market Size by Type (2019-2024) & ($ Millions)
Table 38. Europe Neurodegenerative Diseases Therapeutics Market Size Market Share by Type (2019-2024)
Table 39. Europe Neurodegenerative Diseases Therapeutics Market Size by Application (2019-2024) & ($ Millions)
Table 40. Europe Neurodegenerative Diseases Therapeutics Market Size Market Share by Application (2019-2024)
Table 41. Middle East & Africa Neurodegenerative Diseases Therapeutics Market Size by Region (2019-2024) & ($ Millions)
Table 42. Middle East & Africa Neurodegenerative Diseases Therapeutics Market Size Market Share by Region (2019-2024)
Table 43. Middle East & Africa Neurodegenerative Diseases Therapeutics Market Size by Type (2019-2024) & ($ Millions)
Table 44. Middle East & Africa Neurodegenerative Diseases Therapeutics Market Size Market Share by Type (2019-2024)
Table 45. Middle East & Africa Neurodegenerative Diseases Therapeutics Market Size by Application (2019-2024) & ($ Millions)
Table 46. Middle East & Africa Neurodegenerative Diseases Therapeutics Market Size Market Share by Application (2019-2024)
Table 47. Key Market Drivers & Growth Opportunities of Neurodegenerative Diseases Therapeutics
Table 48. Key Market Challenges & Risks of Neurodegenerative Diseases Therapeutics
Table 49. Key Industry Trends of Neurodegenerative Diseases Therapeutics
Table 50. Global Neurodegenerative Diseases Therapeutics Market Size Forecast by Regions (2025-2030) & ($ Millions)
Table 51. Global Neurodegenerative Diseases Therapeutics Market Size Market Share Forecast by Regions (2025-2030)
Table 52. Global Neurodegenerative Diseases Therapeutics Market Size Forecast by Type (2025-2030) & ($ Millions)
Table 53. Global Neurodegenerative Diseases Therapeutics Market Size Forecast by Application (2025-2030) & ($ Millions)
Table 54. AB Science SA Details, Company Type, Neurodegenerative Diseases Therapeutics Area Served and Its Competitors
Table 55. AB Science SA Neurodegenerative Diseases Therapeutics Product Offered
Table 56. AB Science SA Neurodegenerative Diseases Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 57. AB Science SA Main Business
Table 58. AB Science SA Latest Developments
Table 59. AbbVie Inc. Details, Company Type, Neurodegenerative Diseases Therapeutics Area Served and Its Competitors
Table 60. AbbVie Inc. Neurodegenerative Diseases Therapeutics Product Offered
Table 61. AbbVie Inc. Main Business
Table 62. AbbVie Inc. Neurodegenerative Diseases Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 63. AbbVie Inc. Latest Developments
Table 64. Acadia Pharmaceuticals Inc. Details, Company Type, Neurodegenerative Diseases Therapeutics Area Served and Its Competitors
Table 65. Acadia Pharmaceuticals Inc. Neurodegenerative Diseases Therapeutics Product Offered
Table 66. Acadia Pharmaceuticals Inc. Main Business
Table 67. Acadia Pharmaceuticals Inc. Neurodegenerative Diseases Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 68. Acadia Pharmaceuticals Inc. Latest Developments
Table 69. Biogen Inc. Details, Company Type, Neurodegenerative Diseases Therapeutics Area Served and Its Competitors
Table 70. Biogen Inc. Neurodegenerative Diseases Therapeutics Product Offered
Table 71. Biogen Inc. Main Business
Table 72. Biogen Inc. Neurodegenerative Diseases Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 73. Biogen Inc. Latest Developments
Table 74. F. Hoffmann La Roche Ltd. Details, Company Type, Neurodegenerative Diseases Therapeutics Area Served and Its Competitors
Table 75. F. Hoffmann La Roche Ltd. Neurodegenerative Diseases Therapeutics Product Offered
Table 76. F. Hoffmann La Roche Ltd. Main Business
Table 77. F. Hoffmann La Roche Ltd. Neurodegenerative Diseases Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 78. F. Hoffmann La Roche Ltd. Latest Developments
Table 79. H Lundbeck AS Details, Company Type, Neurodegenerative Diseases Therapeutics Area Served and Its Competitors
Table 80. H Lundbeck AS Neurodegenerative Diseases Therapeutics Product Offered
Table 81. H Lundbeck AS Main Business
Table 82. H Lundbeck AS Neurodegenerative Diseases Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 83. H Lundbeck AS Latest Developments
Table 84. Mitsubishi Chemical Holdings Corp. Details, Company Type, Neurodegenerative Diseases Therapeutics Area Served and Its Competitors
Table 85. Mitsubishi Chemical Holdings Corp. Neurodegenerative Diseases Therapeutics Product Offered
Table 86. Mitsubishi Chemical Holdings Corp. Main Business
Table 87. Mitsubishi Chemical Holdings Corp. Neurodegenerative Diseases Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 88. Mitsubishi Chemical Holdings Corp. Latest Developments
Table 89. Novartis AG Details, Company Type, Neurodegenerative Diseases Therapeutics Area Served and Its Competitors
Table 90. Novartis AG Neurodegenerative Diseases Therapeutics Product Offered
Table 91. Novartis AG Main Business
Table 92. Novartis AG Neurodegenerative Diseases Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 93. Novartis AG Latest Developments
Table 94. Sanofi Details, Company Type, Neurodegenerative Diseases Therapeutics Area Served and Its Competitors
Table 95. Sanofi Neurodegenerative Diseases Therapeutics Product Offered
Table 96. Sanofi Main Business
Table 97. Sanofi Neurodegenerative Diseases Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 98. Sanofi Latest Developments
Table 99. Teva Pharmaceutical Industries Ltd Details, Company Type, Neurodegenerative Diseases Therapeutics Area Served and Its Competitors
Table 100. Teva Pharmaceutical Industries Ltd Neurodegenerative Diseases Therapeutics Product Offered
Table 101. Teva Pharmaceutical Industries Ltd Main Business
Table 102. Teva Pharmaceutical Industries Ltd Neurodegenerative Diseases Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 103. Teva Pharmaceutical Industries Ltd Latest Developments
Table 1. Neurodegenerative Diseases Therapeutics Market Size CAGR by Region (2019 VS 2023 VS 2030) & ($ Millions)
Table 2. Major Players of Multiple Sclerosis Therapeutics
Table 3. Major Players of Alzheimer's Disease Therapeutics
Table 4. Major Players of Parkinson's Disease Therapeutics
Table 5. Major Players of Parkinson's Disease Therapeutics
Table 6. Major Players of Others
Table 7. Neurodegenerative Diseases Therapeutics Market Size CAGR by Type (2019 VS 2023 VS 2030) & ($ Millions)
Table 8. Global Neurodegenerative Diseases Therapeutics Market Size by Type (2019-2024) & ($ Millions)
Table 9. Global Neurodegenerative Diseases Therapeutics Market Size Market Share by Type (2019-2024)
Table 10. Neurodegenerative Diseases Therapeutics Market Size CAGR by Application (2019 VS 2023 VS 2030) & ($ Millions)
Table 11. Global Neurodegenerative Diseases Therapeutics Market Size by Application (2019-2024) & ($ Millions)
Table 12. Global Neurodegenerative Diseases Therapeutics Market Size Market Share by Application (2019-2024)
Table 13. Global Neurodegenerative Diseases Therapeutics Revenue by Players (2019-2024) & ($ Millions)
Table 14. Global Neurodegenerative Diseases Therapeutics Revenue Market Share by Player (2019-2024)
Table 15. Neurodegenerative Diseases Therapeutics Key Players Head office and Products Offered
Table 16. Neurodegenerative Diseases Therapeutics Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
Table 17. New Products and Potential Entrants
Table 18. Mergers & Acquisitions, Expansion
Table 19. Global Neurodegenerative Diseases Therapeutics Market Size by Regions 2019-2024 & ($ Millions)
Table 20. Global Neurodegenerative Diseases Therapeutics Market Size Market Share by Regions (2019-2024)
Table 21. Global Neurodegenerative Diseases Therapeutics Revenue by Country/Region (2019-2024) & ($ millions)
Table 22. Global Neurodegenerative Diseases Therapeutics Revenue Market Share by Country/Region (2019-2024)
Table 23. Americas Neurodegenerative Diseases Therapeutics Market Size by Country (2019-2024) & ($ Millions)
Table 24. Americas Neurodegenerative Diseases Therapeutics Market Size Market Share by Country (2019-2024)
Table 25. Americas Neurodegenerative Diseases Therapeutics Market Size by Type (2019-2024) & ($ Millions)
Table 26. Americas Neurodegenerative Diseases Therapeutics Market Size Market Share by Type (2019-2024)
Table 27. Americas Neurodegenerative Diseases Therapeutics Market Size by Application (2019-2024) & ($ Millions)
Table 28. Americas Neurodegenerative Diseases Therapeutics Market Size Market Share by Application (2019-2024)
Table 29. APAC Neurodegenerative Diseases Therapeutics Market Size by Region (2019-2024) & ($ Millions)
Table 30. APAC Neurodegenerative Diseases Therapeutics Market Size Market Share by Region (2019-2024)
Table 31. APAC Neurodegenerative Diseases Therapeutics Market Size by Type (2019-2024) & ($ Millions)
Table 32. APAC Neurodegenerative Diseases Therapeutics Market Size Market Share by Type (2019-2024)
Table 33. APAC Neurodegenerative Diseases Therapeutics Market Size by Application (2019-2024) & ($ Millions)
Table 34. APAC Neurodegenerative Diseases Therapeutics Market Size Market Share by Application (2019-2024)
Table 35. Europe Neurodegenerative Diseases Therapeutics Market Size by Country (2019-2024) & ($ Millions)
Table 36. Europe Neurodegenerative Diseases Therapeutics Market Size Market Share by Country (2019-2024)
Table 37. Europe Neurodegenerative Diseases Therapeutics Market Size by Type (2019-2024) & ($ Millions)
Table 38. Europe Neurodegenerative Diseases Therapeutics Market Size Market Share by Type (2019-2024)
Table 39. Europe Neurodegenerative Diseases Therapeutics Market Size by Application (2019-2024) & ($ Millions)
Table 40. Europe Neurodegenerative Diseases Therapeutics Market Size Market Share by Application (2019-2024)
Table 41. Middle East & Africa Neurodegenerative Diseases Therapeutics Market Size by Region (2019-2024) & ($ Millions)
Table 42. Middle East & Africa Neurodegenerative Diseases Therapeutics Market Size Market Share by Region (2019-2024)
Table 43. Middle East & Africa Neurodegenerative Diseases Therapeutics Market Size by Type (2019-2024) & ($ Millions)
Table 44. Middle East & Africa Neurodegenerative Diseases Therapeutics Market Size Market Share by Type (2019-2024)
Table 45. Middle East & Africa Neurodegenerative Diseases Therapeutics Market Size by Application (2019-2024) & ($ Millions)
Table 46. Middle East & Africa Neurodegenerative Diseases Therapeutics Market Size Market Share by Application (2019-2024)
Table 47. Key Market Drivers & Growth Opportunities of Neurodegenerative Diseases Therapeutics
Table 48. Key Market Challenges & Risks of Neurodegenerative Diseases Therapeutics
Table 49. Key Industry Trends of Neurodegenerative Diseases Therapeutics
Table 50. Global Neurodegenerative Diseases Therapeutics Market Size Forecast by Regions (2025-2030) & ($ Millions)
Table 51. Global Neurodegenerative Diseases Therapeutics Market Size Market Share Forecast by Regions (2025-2030)
Table 52. Global Neurodegenerative Diseases Therapeutics Market Size Forecast by Type (2025-2030) & ($ Millions)
Table 53. Global Neurodegenerative Diseases Therapeutics Market Size Forecast by Application (2025-2030) & ($ Millions)
Table 54. AB Science SA Details, Company Type, Neurodegenerative Diseases Therapeutics Area Served and Its Competitors
Table 55. AB Science SA Neurodegenerative Diseases Therapeutics Product Offered
Table 56. AB Science SA Neurodegenerative Diseases Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 57. AB Science SA Main Business
Table 58. AB Science SA Latest Developments
Table 59. AbbVie Inc. Details, Company Type, Neurodegenerative Diseases Therapeutics Area Served and Its Competitors
Table 60. AbbVie Inc. Neurodegenerative Diseases Therapeutics Product Offered
Table 61. AbbVie Inc. Main Business
Table 62. AbbVie Inc. Neurodegenerative Diseases Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 63. AbbVie Inc. Latest Developments
Table 64. Acadia Pharmaceuticals Inc. Details, Company Type, Neurodegenerative Diseases Therapeutics Area Served and Its Competitors
Table 65. Acadia Pharmaceuticals Inc. Neurodegenerative Diseases Therapeutics Product Offered
Table 66. Acadia Pharmaceuticals Inc. Main Business
Table 67. Acadia Pharmaceuticals Inc. Neurodegenerative Diseases Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 68. Acadia Pharmaceuticals Inc. Latest Developments
Table 69. Biogen Inc. Details, Company Type, Neurodegenerative Diseases Therapeutics Area Served and Its Competitors
Table 70. Biogen Inc. Neurodegenerative Diseases Therapeutics Product Offered
Table 71. Biogen Inc. Main Business
Table 72. Biogen Inc. Neurodegenerative Diseases Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 73. Biogen Inc. Latest Developments
Table 74. F. Hoffmann La Roche Ltd. Details, Company Type, Neurodegenerative Diseases Therapeutics Area Served and Its Competitors
Table 75. F. Hoffmann La Roche Ltd. Neurodegenerative Diseases Therapeutics Product Offered
Table 76. F. Hoffmann La Roche Ltd. Main Business
Table 77. F. Hoffmann La Roche Ltd. Neurodegenerative Diseases Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 78. F. Hoffmann La Roche Ltd. Latest Developments
Table 79. H Lundbeck AS Details, Company Type, Neurodegenerative Diseases Therapeutics Area Served and Its Competitors
Table 80. H Lundbeck AS Neurodegenerative Diseases Therapeutics Product Offered
Table 81. H Lundbeck AS Main Business
Table 82. H Lundbeck AS Neurodegenerative Diseases Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 83. H Lundbeck AS Latest Developments
Table 84. Mitsubishi Chemical Holdings Corp. Details, Company Type, Neurodegenerative Diseases Therapeutics Area Served and Its Competitors
Table 85. Mitsubishi Chemical Holdings Corp. Neurodegenerative Diseases Therapeutics Product Offered
Table 86. Mitsubishi Chemical Holdings Corp. Main Business
Table 87. Mitsubishi Chemical Holdings Corp. Neurodegenerative Diseases Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 88. Mitsubishi Chemical Holdings Corp. Latest Developments
Table 89. Novartis AG Details, Company Type, Neurodegenerative Diseases Therapeutics Area Served and Its Competitors
Table 90. Novartis AG Neurodegenerative Diseases Therapeutics Product Offered
Table 91. Novartis AG Main Business
Table 92. Novartis AG Neurodegenerative Diseases Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 93. Novartis AG Latest Developments
Table 94. Sanofi Details, Company Type, Neurodegenerative Diseases Therapeutics Area Served and Its Competitors
Table 95. Sanofi Neurodegenerative Diseases Therapeutics Product Offered
Table 96. Sanofi Main Business
Table 97. Sanofi Neurodegenerative Diseases Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 98. Sanofi Latest Developments
Table 99. Teva Pharmaceutical Industries Ltd Details, Company Type, Neurodegenerative Diseases Therapeutics Area Served and Its Competitors
Table 100. Teva Pharmaceutical Industries Ltd Neurodegenerative Diseases Therapeutics Product Offered
Table 101. Teva Pharmaceutical Industries Ltd Main Business
Table 102. Teva Pharmaceutical Industries Ltd Neurodegenerative Diseases Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 103. Teva Pharmaceutical Industries Ltd Latest Developments
LIST OF FIGURES
Figure 1. Neurodegenerative Diseases Therapeutics Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Neurodegenerative Diseases Therapeutics Market Size Growth Rate 2019-2030 ($ Millions)
Figure 6. Neurodegenerative Diseases Therapeutics Sales by Geographic Region (2019, 2023 & 2030) & ($ millions)
Figure 7. Neurodegenerative Diseases Therapeutics Sales Market Share by Country/Region (2023)
Figure 8. Neurodegenerative Diseases Therapeutics Sales Market Share by Country/Region (2019, 2023 & 2030)
Figure 9. Global Neurodegenerative Diseases Therapeutics Market Size Market Share by Type in 2023
Figure 10. Neurodegenerative Diseases Therapeutics in Child
Figure 11. Global Neurodegenerative Diseases Therapeutics Market: Child (2019-2024) & ($ Millions)
Figure 12. Neurodegenerative Diseases Therapeutics in Aldult
Figure 13. Global Neurodegenerative Diseases Therapeutics Market: Aldult (2019-2024) & ($ Millions)
Figure 14. Global Neurodegenerative Diseases Therapeutics Market Size Market Share by Application in 2023
Figure 15. Global Neurodegenerative Diseases Therapeutics Revenue Market Share by Player in 2023
Figure 16. Global Neurodegenerative Diseases Therapeutics Market Size Market Share by Regions (2019-2024)
Figure 17. Americas Neurodegenerative Diseases Therapeutics Market Size 2019-2024 ($ Millions)
Figure 18. APAC Neurodegenerative Diseases Therapeutics Market Size 2019-2024 ($ Millions)
Figure 19. Europe Neurodegenerative Diseases Therapeutics Market Size 2019-2024 ($ Millions)
Figure 20. Middle East & Africa Neurodegenerative Diseases Therapeutics Market Size 2019-2024 ($ Millions)
Figure 21. Americas Neurodegenerative Diseases Therapeutics Value Market Share by Country in 2023
Figure 22. United States Neurodegenerative Diseases Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 23. Canada Neurodegenerative Diseases Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 24. Mexico Neurodegenerative Diseases Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 25. Brazil Neurodegenerative Diseases Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 26. APAC Neurodegenerative Diseases Therapeutics Market Size Market Share by Region in 2023
Figure 27. APAC Neurodegenerative Diseases Therapeutics Market Size Market Share by Type in 2023
Figure 28. APAC Neurodegenerative Diseases Therapeutics Market Size Market Share by Application in 2023
Figure 29. China Neurodegenerative Diseases Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 30. Japan Neurodegenerative Diseases Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 31. Korea Neurodegenerative Diseases Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 32. Southeast Asia Neurodegenerative Diseases Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 33. India Neurodegenerative Diseases Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 34. Australia Neurodegenerative Diseases Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 35. Europe Neurodegenerative Diseases Therapeutics Market Size Market Share by Country in 2023
Figure 36. Europe Neurodegenerative Diseases Therapeutics Market Size Market Share by Type (2019-2024)
Figure 37. Europe Neurodegenerative Diseases Therapeutics Market Size Market Share by Application (2019-2024)
Figure 38. Germany Neurodegenerative Diseases Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 39. France Neurodegenerative Diseases Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 40. UK Neurodegenerative Diseases Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 41. Italy Neurodegenerative Diseases Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 42. Russia Neurodegenerative Diseases Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 43. Middle East & Africa Neurodegenerative Diseases Therapeutics Market Size Market Share by Region (2019-2024)
Figure 44. Middle East & Africa Neurodegenerative Diseases Therapeutics Market Size Market Share by Type (2019-2024)
Figure 45. Middle East & Africa Neurodegenerative Diseases Therapeutics Market Size Market Share by Application (2019-2024)
Figure 46. Egypt Neurodegenerative Diseases Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 47. South Africa Neurodegenerative Diseases Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 48. Israel Neurodegenerative Diseases Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 49. Turkey Neurodegenerative Diseases Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 50. GCC Country Neurodegenerative Diseases Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 51. Americas Neurodegenerative Diseases Therapeutics Market Size 2025-2030 ($ Millions)
Figure 52. APAC Neurodegenerative Diseases Therapeutics Market Size 2025-2030 ($ Millions)
Figure 53. Europe Neurodegenerative Diseases Therapeutics Market Size 2025-2030 ($ Millions)
Figure 54. Middle East & Africa Neurodegenerative Diseases Therapeutics Market Size 2025-2030 ($ Millions)
Figure 55. United States Neurodegenerative Diseases Therapeutics Market Size 2025-2030 ($ Millions)
Figure 56. Canada Neurodegenerative Diseases Therapeutics Market Size 2025-2030 ($ Millions)
Figure 57. Mexico Neurodegenerative Diseases Therapeutics Market Size 2025-2030 ($ Millions)
Figure 58. Brazil Neurodegenerative Diseases Therapeutics Market Size 2025-2030 ($ Millions)
Figure 59. China Neurodegenerative Diseases Therapeutics Market Size 2025-2030 ($ Millions)
Figure 60. Japan Neurodegenerative Diseases Therapeutics Market Size 2025-2030 ($ Millions)
Figure 61. Korea Neurodegenerative Diseases Therapeutics Market Size 2025-2030 ($ Millions)
Figure 62. Southeast Asia Neurodegenerative Diseases Therapeutics Market Size 2025-2030 ($ Millions)
Figure 63. India Neurodegenerative Diseases Therapeutics Market Size 2025-2030 ($ Millions)
Figure 64. Australia Neurodegenerative Diseases Therapeutics Market Size 2025-2030 ($ Millions)
Figure 65. Germany Neurodegenerative Diseases Therapeutics Market Size 2025-2030 ($ Millions)
Figure 66. France Neurodegenerative Diseases Therapeutics Market Size 2025-2030 ($ Millions)
Figure 67. UK Neurodegenerative Diseases Therapeutics Market Size 2025-2030 ($ Millions)
Figure 68. Italy Neurodegenerative Diseases Therapeutics Market Size 2025-2030 ($ Millions)
Figure 69. Russia Neurodegenerative Diseases Therapeutics Market Size 2025-2030 ($ Millions)
Figure 70. Spain Neurodegenerative Diseases Therapeutics Market Size 2025-2030 ($ Millions)
Figure 71. Egypt Neurodegenerative Diseases Therapeutics Market Size 2025-2030 ($ Millions)
Figure 72. South Africa Neurodegenerative Diseases Therapeutics Market Size 2025-2030 ($ Millions)
Figure 73. Israel Neurodegenerative Diseases Therapeutics Market Size 2025-2030 ($ Millions)
Figure 74. Turkey Neurodegenerative Diseases Therapeutics Market Size 2025-2030 ($ Millions)
Figure 75. GCC Countries Neurodegenerative Diseases Therapeutics Market Size 2025-2030 ($ Millions)
Figure 76. Global Neurodegenerative Diseases Therapeutics Market Size Market Share Forecast by Type (2025-2030)
Figure 77. Global Neurodegenerative Diseases Therapeutics Market Size Market Share Forecast by Application (2025-2030)
Figure 1. Neurodegenerative Diseases Therapeutics Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Neurodegenerative Diseases Therapeutics Market Size Growth Rate 2019-2030 ($ Millions)
Figure 6. Neurodegenerative Diseases Therapeutics Sales by Geographic Region (2019, 2023 & 2030) & ($ millions)
Figure 7. Neurodegenerative Diseases Therapeutics Sales Market Share by Country/Region (2023)
Figure 8. Neurodegenerative Diseases Therapeutics Sales Market Share by Country/Region (2019, 2023 & 2030)
Figure 9. Global Neurodegenerative Diseases Therapeutics Market Size Market Share by Type in 2023
Figure 10. Neurodegenerative Diseases Therapeutics in Child
Figure 11. Global Neurodegenerative Diseases Therapeutics Market: Child (2019-2024) & ($ Millions)
Figure 12. Neurodegenerative Diseases Therapeutics in Aldult
Figure 13. Global Neurodegenerative Diseases Therapeutics Market: Aldult (2019-2024) & ($ Millions)
Figure 14. Global Neurodegenerative Diseases Therapeutics Market Size Market Share by Application in 2023
Figure 15. Global Neurodegenerative Diseases Therapeutics Revenue Market Share by Player in 2023
Figure 16. Global Neurodegenerative Diseases Therapeutics Market Size Market Share by Regions (2019-2024)
Figure 17. Americas Neurodegenerative Diseases Therapeutics Market Size 2019-2024 ($ Millions)
Figure 18. APAC Neurodegenerative Diseases Therapeutics Market Size 2019-2024 ($ Millions)
Figure 19. Europe Neurodegenerative Diseases Therapeutics Market Size 2019-2024 ($ Millions)
Figure 20. Middle East & Africa Neurodegenerative Diseases Therapeutics Market Size 2019-2024 ($ Millions)
Figure 21. Americas Neurodegenerative Diseases Therapeutics Value Market Share by Country in 2023
Figure 22. United States Neurodegenerative Diseases Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 23. Canada Neurodegenerative Diseases Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 24. Mexico Neurodegenerative Diseases Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 25. Brazil Neurodegenerative Diseases Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 26. APAC Neurodegenerative Diseases Therapeutics Market Size Market Share by Region in 2023
Figure 27. APAC Neurodegenerative Diseases Therapeutics Market Size Market Share by Type in 2023
Figure 28. APAC Neurodegenerative Diseases Therapeutics Market Size Market Share by Application in 2023
Figure 29. China Neurodegenerative Diseases Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 30. Japan Neurodegenerative Diseases Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 31. Korea Neurodegenerative Diseases Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 32. Southeast Asia Neurodegenerative Diseases Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 33. India Neurodegenerative Diseases Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 34. Australia Neurodegenerative Diseases Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 35. Europe Neurodegenerative Diseases Therapeutics Market Size Market Share by Country in 2023
Figure 36. Europe Neurodegenerative Diseases Therapeutics Market Size Market Share by Type (2019-2024)
Figure 37. Europe Neurodegenerative Diseases Therapeutics Market Size Market Share by Application (2019-2024)
Figure 38. Germany Neurodegenerative Diseases Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 39. France Neurodegenerative Diseases Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 40. UK Neurodegenerative Diseases Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 41. Italy Neurodegenerative Diseases Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 42. Russia Neurodegenerative Diseases Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 43. Middle East & Africa Neurodegenerative Diseases Therapeutics Market Size Market Share by Region (2019-2024)
Figure 44. Middle East & Africa Neurodegenerative Diseases Therapeutics Market Size Market Share by Type (2019-2024)
Figure 45. Middle East & Africa Neurodegenerative Diseases Therapeutics Market Size Market Share by Application (2019-2024)
Figure 46. Egypt Neurodegenerative Diseases Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 47. South Africa Neurodegenerative Diseases Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 48. Israel Neurodegenerative Diseases Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 49. Turkey Neurodegenerative Diseases Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 50. GCC Country Neurodegenerative Diseases Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 51. Americas Neurodegenerative Diseases Therapeutics Market Size 2025-2030 ($ Millions)
Figure 52. APAC Neurodegenerative Diseases Therapeutics Market Size 2025-2030 ($ Millions)
Figure 53. Europe Neurodegenerative Diseases Therapeutics Market Size 2025-2030 ($ Millions)
Figure 54. Middle East & Africa Neurodegenerative Diseases Therapeutics Market Size 2025-2030 ($ Millions)
Figure 55. United States Neurodegenerative Diseases Therapeutics Market Size 2025-2030 ($ Millions)
Figure 56. Canada Neurodegenerative Diseases Therapeutics Market Size 2025-2030 ($ Millions)
Figure 57. Mexico Neurodegenerative Diseases Therapeutics Market Size 2025-2030 ($ Millions)
Figure 58. Brazil Neurodegenerative Diseases Therapeutics Market Size 2025-2030 ($ Millions)
Figure 59. China Neurodegenerative Diseases Therapeutics Market Size 2025-2030 ($ Millions)
Figure 60. Japan Neurodegenerative Diseases Therapeutics Market Size 2025-2030 ($ Millions)
Figure 61. Korea Neurodegenerative Diseases Therapeutics Market Size 2025-2030 ($ Millions)
Figure 62. Southeast Asia Neurodegenerative Diseases Therapeutics Market Size 2025-2030 ($ Millions)
Figure 63. India Neurodegenerative Diseases Therapeutics Market Size 2025-2030 ($ Millions)
Figure 64. Australia Neurodegenerative Diseases Therapeutics Market Size 2025-2030 ($ Millions)
Figure 65. Germany Neurodegenerative Diseases Therapeutics Market Size 2025-2030 ($ Millions)
Figure 66. France Neurodegenerative Diseases Therapeutics Market Size 2025-2030 ($ Millions)
Figure 67. UK Neurodegenerative Diseases Therapeutics Market Size 2025-2030 ($ Millions)
Figure 68. Italy Neurodegenerative Diseases Therapeutics Market Size 2025-2030 ($ Millions)
Figure 69. Russia Neurodegenerative Diseases Therapeutics Market Size 2025-2030 ($ Millions)
Figure 70. Spain Neurodegenerative Diseases Therapeutics Market Size 2025-2030 ($ Millions)
Figure 71. Egypt Neurodegenerative Diseases Therapeutics Market Size 2025-2030 ($ Millions)
Figure 72. South Africa Neurodegenerative Diseases Therapeutics Market Size 2025-2030 ($ Millions)
Figure 73. Israel Neurodegenerative Diseases Therapeutics Market Size 2025-2030 ($ Millions)
Figure 74. Turkey Neurodegenerative Diseases Therapeutics Market Size 2025-2030 ($ Millions)
Figure 75. GCC Countries Neurodegenerative Diseases Therapeutics Market Size 2025-2030 ($ Millions)
Figure 76. Global Neurodegenerative Diseases Therapeutics Market Size Market Share Forecast by Type (2025-2030)
Figure 77. Global Neurodegenerative Diseases Therapeutics Market Size Market Share Forecast by Application (2025-2030)
